anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There are few studies on the connection between food components and circular RNA (circRNA), a type of noncoding RNA that is significant for living organisms. (-)-Epigallocatechin-3-O-gallate (EGCG) has been reported to have various biological effects, and elucidation of the molecular mechanism is important for clarifying the functionality of EGCG. In the current study, we looked at how EGCG regulates the expression of circRNA in the liver, which expresses a lot of circRNAs. Mice were given EGCG (10 mg/kg b.w.) orally for one week before circRNA microarray testing was done on their livers. The microarray analysis revealed that mice treated with EGCG had altered expression of 35 circRNAs in their livers. To clarify the function of mmu_circRNA_011775, one of the circRNAs upregulated by EGCG, mouse liver cells after the mmu_circRNA_011775 expression vector was transfected into NMuLi cells, next-generation sequencing (NGS) was used to analyze the gene expression. NGS analysis shows that the expression of the genes responsible for liver fibrosis and inflammation. Gene ontology (GO) analysis showed that mmu_circRNA_011775 changed the meaning of GO terms associated with the cardiovascular system. In the microarray, EGCG altered 35 genes expression. Among them, pre-ribosomal RNA-derived circRNA mmu_circRNA_011775 regulated the expression of various genes related to liver fibrosis and cardiovascular system.
After enrollment and randomization, patients allocated to this arm receives REBOA in addition to conventional ACLS according to the 2020 AHA CPR guidelines. The common femoral artery is accessed with ultrasound guidance. A sheath catheter is inserted, followed by a REBOA catheter. The REBOA is ballooned with 20cc of normal saline or until resistance is felt.
Group A included 30 patients treated with one 0.5mg intravitreal ranibizumab injection. All patients were followed monthly for 12 months with additional injections performed as needed.
A pharmaceutical compsn. with Factor VIII inhibitor bypass activity (FEIBA) contains Factor VIIa and ≥ 1 other active substance, and has an activity of ≥ 10 Factor VIIa units per unit of FEIBA. The additional active substance comprises clotting factors II, IX and X, each pref. in a ratio of 0.5-2 (esp. 0.5-1.5) units/unit of FEIBA, opt. together with Protein C and/or Protein S.
Participants will be asked to complete a brief screening assessment to establish their eligibility for participation. Eligible participants will be asked to complete a consent form and be directed to the pre-test survey. Upon completion of the survey, the participants will be directed to the tailored intervention content, including the Parents' Stories videos. This step will be completed prior to interaction with the provider. During the provider-patient visit, the provider will deliver the elaborated prompt portion of the intervention to participating mothers. Mothers will receive a link to the post-test survey two weeks following their appointment.
The utilization of Artificial Intelligence (AI) and Machine Learning (ML) is paving the way for significant strides in patient diagnosis, treatment, and prognostication in neurocritical care. These technologies offer the potential to unravel complex patterns within vast datasets ranging from vast clinical data and EEG (electroencephalogram) readings to advanced cerebral imaging facilitating a more nuanced understanding of patient conditions. Despite their promise, the implementation of AI and ML faces substantial hurdles. Historical biases within training data, the challenge of interpreting multifaceted data streams, and the "black box" nature of ML algorithms present barriers to widespread clinical adoption. Moreover, ethical considerations around data privacy and the need for transparent, explainable models remain paramount to ensure trust and efficacy in clinical decision-making.This article reflects on the emergence of AI and ML as integral tools in neurocritical care, discussing their roles from the perspective of both their scientific promise and the associated challenges. We underscore the importance of extensive validation in diverse clinical settings to ensure the generalizability of ML models, particularly considering their potential to inform critical medical decisions such as withdrawal of life-sustaining therapies. Advancement in computational capabilities is essential for implementing ML in clinical settings, allowing for real-time analysis and decision support at the point of care. As AI and ML are poised to become commonplace in clinical practice, it is incumbent upon health care professionals to understand and oversee these technologies, ensuring they adhere to the highest safety standards and contribute to the realization of personalized medicine. This engagement will be pivotal in integrating AI and ML into patient care, optimizing outcomes in neurocritical care through informed and data-driven decision-making.
The formulation includes 2% pure raw propolis, 40 ml flavors, 150 ml propylene glycol, 60 gm sorbitol, 0.1 g coloring substance and water. Children will be instructed to rinse using the prepared propolis mouthwash for 1 min, twice a day, after breakfast and before bedtime.
Citrus bacterial canker (CBC) is a disease that poses a major threat to global citrus production and is caused by infection with Xanthomonas citri subsp. citri (Xcc). Wall-associated receptor-like kinase (WAKL) proteins play an important role in shaping plant resistance to various bacterial and fungal pathogens. In a previous report, CsWAKL01 was identified as a candidate Xcc-inducible gene found to be up-regulated in CBC-resistant citrus plants. However, the functional role of CsWAKL01 and the mechanisms whereby it may influence resistance to CBC have yet to be clarified. Here, CsWAKL01 was found to localize to the plasma membrane, and the overexpression of the corresponding gene in transgenic sweet oranges resulted in pronounced enhancement of CBC resistance, whereas its knockdown had the opposite effect. Mechanistically, the effect of CsWAKL01 was linked to its ability to reprogram jasmonic acid, salicylic acid, and abscisic acid signaling activity. CsWRKY53 was further identified as a transcription factor capable of directly binding to the CsWAKL01 promoter and inducing its transcriptional up-regulation. CsWRKY53 silencing conferred greater CBC susceptibility to infected plants. Overall, these data support a model wherein CsWRKY53 functions as a positive regulator of CsWAKL01 to enhance resistance to CBC via the reprogramming of phytohormone signaling. Together these results offer new insights into the mechanisms whereby WAKLs shape phytopathogen resistance while underscoring the potential value of targeting the CsWRKY53-CsWAKL01 axis when seeking to breed CBC-resistant citrus plant varieties.
Circular RNAs (CircRNAs) are non-coding RNAs (ncRNAs) characterized by a stable circular structure that regulates gene expression at both transcriptional and post-transcriptional levels. They play diverse roles, including protein interactions, DNA methylation modification, protein-coding potential, pseudogene creation, and miRNA sponging, all of which influence various physiological processes. CircRNAs are often highly expressed in brain tissues, and their levels vary with neural development, suggesting their significance in nervous system diseases such as gliomas. Research has shown that circRNA expression related to the PI3K pathway correlates with various clinical features of gliomas. There is an interact between circRNAs and the PI3K pathway to regulate glioma cell processes such as proliferation, differentiation, apoptosis, inflammation, angiogenesis, and treatment resistance. Additionally, PI3K pathway-associated circRNAs hold potential as biomarkers for cancer diagnosis, prognosis, and treatment. In this study, we reviewed the latest advances in the expression and cellular roles of PI3K-mediated circRNAs and their connections to glioma carcinogenesis and progression. We also highlighted the significance of circRNAs as diagnostic and prognostic biomarkers and therapeutic targets in glioma.
Headaches and epilepsy are chronic disorders with episodic manifestations characterized by recurrent attacks of nervous system dysfunction with a return to baseline between attacks. Although it is not uncommon that patients with epilepsy suffer from headaches, the relations between seizures and headaches is multi-factorial. Headaches may occur immediately before (preictal), during (ictal), or after (postictal) a seizure. In addition to seizure-associated headaches, patients often experience headaches that are not temporally related to seizures-interictal headaches. Moreover, epidemiological studies indicate an association of migraine and epilepsy with an increased prevalence of migraine in patients with epilepsy. Up to now, there is still limited information about the relationship between the frequency of seizure attacks and headache occurrences. Thus, we purpose this study to investigate the incidence of headaches, to explore the relationship between seizure attacks and headache occurrences, to classify the headache, and to document the frequency, characteristics, and effects of migraine and headaches among patients with epilepsy. This study is a multi-centre survey to collect data from patients who are diagnosed with epilepsy and are followed up in epilepsy clinics. Patients can only participate in this study after signing and dating the inform consents. There are two stages of this study: Stage I: On enrollment, data on demographic characteristics, epilepsy profile, seizure frequencies, and epilepsy treatment would be obtained. Body weight and height would be measured. Information of prior headache occurrences and their relationships with seizures would also be collected. Stage II: Patients enrolled into this study will be divided into three group: patients who are seizure free for past 6 months, patients with \> 1 attack every month within past 6 months, and other patients. Participants of each group will be enrolled into Stage II for 24-week follow-up. Information of seizure attacks, headache occurrences, and treatment will be collected. This is an observational study and no study drug is administered.
BACKGROUND: Ticagrelor is recommended over clopidogrel in acute coronary syndrome based on the results of the PLATO (Study of Platelet Inhibition and Patient Outcomes) trial. We aimed to emulate PLATO in older adults with and without frailty and with acute coronary syndrome treated with percutaneous coronary intervention.
METHODS AND RESULTS: We created a new-user cohort of Medicare fee-for-service beneficiaries aged ≥65 years hospitalized for acute coronary syndrome from 2014 to 2018 and initiated ticagrelor or clopidogrel following percutaneous coronary intervention. Frailty was defined using a validated claims-based frailty index ≥0.25. Coprimary outcomes were major adverse cardiovascular events and major bleeding. Follow-up began on the date of first outpatient prescription for ticagrelor or clopidogrel and ended on the earliest date for an outcome event, death, discontinuation of the index drug, or disenrollment from Medicare. The study included 42 843 older adults; 23% were frail. After propensity score matching, the rates of major adverse cardiovascular events per 100 person-years comparing ticagrelor versus clopidogrel groups were 7.8 and 7.3 in the frail cohort (hazard ratio [HR], 1.07 [95% CI, 0.84-1.36]) and 3.7 and 4.2 in the nonfrail cohort (HR, 0.87 [95% CI, 0.75-1.02]). The corresponding rates of major bleeding were 4.3 and 3.8 in the frail cohort (HR, 1.12 95% CI, [0.80-1.56]) and 2.2 and 1.8 in the nonfrail cohort (HR, 1.22 [95% CI, 0.98-1.51]).
CONCLUSIONS: There was a trend toward a modest reduction in risk of major adverse cardiovascular events and a trend toward a modest increase in risk of major bleeding with ticagrelor compared with clopidogrel in the nonfrail cohort. There was insufficient evidence for the benefit of ticagrelor in frail older adults.
Disclosed is the murine monoclonal antibody ('mAb') TES-C21, and the chimeric mouse/human mAb TESC-2, which has its variable regions derived from TES-C21, and has human (η1,λ) constant regions. Both TES-C21 and TESC-2 bind specifically to IgE and are not reactive with other heavy chain isotypes. Both mAbs bind specifically to IgE secreting B cells, and are not reactive with other leukocytic cell types. Neither antibody binds to IgE bound to FcεRII and both mAbs inhibit the binding of IgE to the low affinity FcεRII receptor on B cells. Neither mAb includes histamine release from human basophils. TESC-2 inhibits the binding of IgE to basophils. These properties make these mAbs well-suited for use in human allergy therapy.
The invention relates to a method for producing molded bodies by injection molding which comprises the following steps: a) melting a (meth)acrylate copolymer that is composed of 30 to 80 % by weight of radically polymerized C1 to C4 alkyl esters of acrylic or methacrylic acid and 70 to 20 % by weight of (meth)acrylate monomers with a tertiary ammonium group in the alkyl group. The (meth)acrylate copolymer used is present in a mixture with 1 to 70 % by weight of a softener and a desiccating agent in a ratio of 1: 1 to 1: 20 and with 0.05 to 5 % by weight of a mold-release agent. In addition, other conventional additives or adjuvants and optionally a pharmaceutically active substance can be present in the mixture. Before melting, the mixture has a content of low-boiling components with a vapor pressure of at least 1.9 bar at 120  DEG C of more than 0.5 % by weight. In step b), the mixture is degassed in the thermoplastic state at temperatures of at least 120  DEG C, thereby reducing the content of low-boiling components with a vapor pressure of at least 1.9 bar at 120  DEG C to not more than 0.5 % by weight. The molten and degassed mixture is c) injected into the mold cavity of an injection mold, the mold cavity having a temperature that is at least 10  DEG C below the glass transition temperature of the (meth)acrylate copolymer. The molten mixture is then cooled off and the molded body obtained is removed from the mold.
Chronic constipation is common among children with ASD and is associated with more severe anxiety, hyperactivity, irritability and repetitive behaviors. Young autistic children with chronic constipation display higher urinary and foecal concentrations of p-cresol, an aromatic compound produced by gut bacteria, known to negatively affect brain function. Acute p-cresol administration to BTBR mice enhances anxiety, hyperactivity and stereotypic behaviors, while blunting social interaction. This study was undertaken to prospectively assess the behavioral effects of gut mobilization in young autistic children with chronic constipation, and to verify their correlation with urinary p-cresol. To this aim, 21 chronically constipated autistic children 2-8 years old were evaluated before (T0), 1 month (T1), and 6 months (T2) after intestinal mobilization, recording Bristol stool scale scores, urinary p-cresol concentrations, and behavioral scores for social interaction deficits, stereotypic behaviors, anxiety, and hyperactivity. Gut mobilization was obtained administering PEG (6.9 g/d once a day) for 6 months. A progressive, statistically significant decrease in all behavioral symptoms was recorded over the six-month study period. Urinary p-cresol levels displayed variable trends, mainly increasing at T1 and decreasing at T2. These results support gut mobilization as a simple strategy to at least partly ameliorate ASD symptoms, as well as comorbid anxiety and hyperactivity, in chronically constipated children. These beneficial effects likely involve multiple mechanisms.
High blood pressure affects approximately 35% of Black men in the United States. This may be due to the fact that Black men frequently have an unusually high number of risk factors for high blood pressure, including diabetes, high stress levels, and increased salt intake and sensitivity. While high blood pressure can often be controlled through diet, lifestyle changes, or medication, it is a chronic asymptomatic medical condition for which individuals should remain under the care of a regular medical provider. A predominantly Black barbershop may be an optimum and receptive setting for an intervention that focuses on improving the detection and treatment of high blood pressure among Black men. In this study, barbers, deemed as influential peers, will be trained to continually monitor their customers' blood pressure, deliver health messages designed to change risk perception and ideas about healthcare utilization, and provide social support for changes in healthcare-seeking behavior and blood pressure levels. The purpose of this study is to evaluate the effectiveness of a barbershop-based intervention at increasing blood pressure awareness and lowering blood pressure levels among Black male customers. With over 18,000 Black barbershops in the United States, the results from this study may be extremely influential in improving the diagnosis and treatment of high blood pressure in Black men.

This study will enroll Black men who are regular customers at a participating barbershop. Each barbershop will be randomly assigned to either a 10-month intervention group or a control group. Nurses will train the intervention group barbers to measure blood pressure and deliver health messages related to blood pressure control during each customer's visit. Before and after the intervention, study researchers will interview barbers and customers over an 8-week period to collect information on blood pressure control. A 12-month follow-up visit will include assessments of blood pressure levels, customer recognition of elevated blood pressure levels, and the number of customers receiving regular medical care.
NEW MATERIAL:The melanin-formation suppressing substance (molecular weight, >=10,000; total nitrogen content, 19.5mg/100ml; specific gravity, 0.996; pH, 6.41). USE:External drug or cosmetic to prevent the formation of melanin pigment or to decolor the pigment. PREPARATION:A fresh term human placenta is washed with ater, sliced, pressed in running water to remove the blood, and thoroughly drained. The product is further sliced, added with an aqueous solution of taurine, and treated with a homogenizer for 20min at 10,000rpm to obtain a slurry. The slurry is extracted under agitation, filtered, adjusted to 4.9-5.0 pH, and stirred to extract the active component from the remaining cells and tissues and to precipitate the proteins, etc. having isoelectric point within the above pH range. The product is cooled and centrifuged. The supernatant liquid is adjusted to 6.3-6.4 pH, heated, centrifuged, adjusted to 7.0 pH, filtered with a membrane filter, and finally subjected to the ultrafiltration to obtain the objective melanin-formation suppressing substance.
PURPOSE: To obtain a cell degeneration suppressing and organ toxicity reducing agent containing a inhibitory substance to serectin of an adhesion molecule on the surface of neutrophiles as a major ingredient. CONSTITUTION: This cell degenerating suppressing and organ toxicity reducing agent comprises containing a serectin inhibitory substance as a major ingredient consisting of one kind or a mixed composition of a sulfoglycolipid derived from an organism (e.g. a sulfatide of formula I and a seminolipid of formula II), a fucosylated glicolipid (e.g. sialyl lewis X or sialyl lewis A) and a synthetic- type sulfurated polysaccharide (e.g. chondroitin surface of heparitin surface). This medicine is used for (a) administering a highly toxic medicine for a long period, (b) suppressing a nephropathy due to a nephrotoxic substance, (c) suppressing a hepatopathy due to a hepatotoxic substance, (d) suppressing a neuropathy due to a cerebral nervotoxic substance and (e) suppressing an organopathy caused by a microorganism.  This medicine is preferably used as an effect activating composition prepared so as to contain 0.005-50wt.% effect activating and stabilizing carrier against 0.005-5wt.% serectin inhibitory substance.
Patients receive fludeoxyglucose F-18 IV over approximately 1 minute and undergo a PET/MRI scan over 70 minutes. Within 5 hours of receiving fludeoxyglucose F-18, patients undergo a repeat PET/MRI scan over 30 minutes. Scans take place within 2 weeks before scheduled surgery and within 4-6 weeks after radiation treatment.
Disclosed are liposomal formulations and biomimetic proteolipid nanoparticles that possess remarkable properties for targeting compounds of interest to particular mammalian cell and tissue types. Leukocyte-based biomimetic nanoparticles are disclosed that incorporate cell membrane proteins to transfer the natural tropism of leukocytes to the final delivery platform. However, tuning the protein integration can affect the in vivo behavior of these nanoparticles and alter their efficacy. Here it is shown that, while increasing the protein:lipid ratio to a maximum of 1:20 (wt./wt.) maintained the nanoparticle's structural properties, increasing protein content resulted in improved targeting of inflamed endothelium in two different animal models. The combined use of a microfluidic, bottom-up approach, and the tuning of key synthesis parameters enabled the synthesis of reproducible, biomimetic nanoparticles for the improved targeted nanodelivery of a variety of inflammatory-based conditions, including particular cancers such as human breast cancer, and TNBC, in particular.
The invention relates to a preparation method of a traditional Chinese medicine for treating hematuresis type acute glomerulonephritis, belonging to the technical field of preparation methods of traditional Chinese medicines. At present, amoxicillin is generally adopted for treating hematuresis type acute glomerulonephritis, but amoxicillin can cause rash accidentally, and after oral administration of high dose, nausea, midsection discomfort, diarrhea and the like can occur. The technical scheme adopted in the invention is as follows: taking garden burnet, pink reineckea herb, plant soot, terra frava usta, crinis carbonisatus, rumex japonicus, marmor serpentinatum, cacumen biotae, madder, common sage herb, white dead nettle, lithospermum, Japanese beauty-berry, flos sophorae, manyleaf paris rhizome, potentilla discolor, radix berberidis, sticktight, Japanese cayratia herb, rubus crataegiflolius Bge., honeysuckle, fructus forsythiae, viola philippica, dandelion, folium isatidis, isatis root, patrinia, cordate houttuynia, Sargent gloryvine, circium japonicum, common cephalanoplos herb and liquorice, soaking the 32 kinds of traditional Chinese medicines in water, and decocting with slow fire, wherein the decocted liquid medicine is the traditional Chinese medicine for treating hematuresis type acute glomerulonephritis. The traditional Chinese medicine for treating hematuresis type acute glomerulonephritis has the advantages of short course of treatment and high cure rate. Assistant and guide are achieved so that the function is just right. Adverse reaction caused by Western medicine is avoided.
In Group 1 pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.